Pharma BD Deal Intelligence

Mankind Pharma Limited / Armed Cell Therapeutics NV (ACTx)

2026 · Acquisition/Merger · $56M · Pending

Mankind Pharma agreed to acquire a 70% controlling stake in Belgium-based Armed Cell Therapeutics (ACTx) for EUR 48M (approximately Rs 511 crore), to be invested in instalments through its Netherlands subsidiary. The transaction marks the Mankind entry into next-generation CAR-T cell therapy and gives it an advanced cell-therapy research platform plus a preclinical pipeline led by programmes in non-Hodgkin lymphoma and small cell lung cancer, including approaches intended to make engineered T cells more persistent and more cytotoxic and to generate CAR-T cells in vivo. The deal is a departure from the prior Mankind M&A pattern, which centred on strengthening its domestic portfolio (Panacea Biotec oncology and transplant brands in 2022, Bharat Serums and Vaccines in 2024).

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals